Background. Approximately 5% of gastrointestinal stromal tumors (GISTs) originate in the rectum, and historically, radical resection was commonly performed. Little is known about the outcome for rectal GIST in the era of imatinib.
small intestine. 4 For unknown reasons, colonic GIST is extraordinarily rare, but rectal GIST is the third most common GIST, representing 1.6-5% of GISTs. 2, [5] [6] [7] [8] The treatment of rectal GIST is particularly challenging due to the anatomic constraints of the bony pelvis. Historically, rectal GIST frequently was treated with radical operations, including abdominoperineal resection or total pelvic exenteration. In the modern era, however, rectal GIST is sometimes resected by local excision via the transanal, transvaginal, or transabdominal approach or by low anterior resection.
Most GISTs are driven by activating mutations in the KIT (75%) or PDGFRa (10%) oncogenes and usually are responsive to the oral tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corporation, Basel, Switzerland). 4 After resection of primary GIST at moderate to high risk of recurrence, adjuvant imatinib has become the standard of care, based on large phase 3 randomized trials showing improved oncologic outcome. 9, 10 Neoadjuvant imatinib is sometimes used in an attempt to downsize locally advanced GISTs and may allow R0 resection in up to 83% of patients. 11 The benefit of neoadjuvant imatinib in rectal GIST is uncertain, although small retrospective series have been reported. [12] [13] [14] [15] In this report, we present the largest single-institution experience with rectal GIST.
METHODS

Patients and Methods
Using a prospectively maintained institutional database, we identified 55 patients with rectal GIST treated at our institution between July 1982 and April 2016. The diagnosis was confirmed with histology and CD117 (KIT), DOG-1 immunohistochemistry, or both. Tumor mutation analysis became routine in the mid-2000s. Risk of recurrence was classified using the Miettinen criteria. 16, 17 The imatinib era was defined as starting in October 2000, when the first patients were treated with the drug at our institution. Institutional Review Board approval was obtained, and research was conducted in compliance with Health Insurance Portability and Accountability Act regulations. Survival and recurrence status was last updated in September 2016.
Statistical Analysis
In this study, overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were measured from the time of surgery and analyzed by the Kaplan-Meier method. Groups were compared using the log-rank test. Continuous variables were compared using Student's t test, and categorical variables were analyzed with the Fisher's exact or the v 2 test, with the level of significance set at 0.05. Analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA).
RESULTS
Patient Characteristics
We excluded eight patients who presented with metastasis or recurrence after undergoing surgery for their primary tumor at another institution. The remaining 47 patients underwent surgery for primary rectal GIST, which represented 7.1% of 663 primary GISTs treated at our institution. Of the 47 patients, 30 underwent surgery in the imatinib era and 17 in the older era ( Table 1 ). The two groups had similar median follow-up evaluation, sex, age, distance from the anal verge, high-risk classification, and mutation type. In the imatinib era, tumors were smaller at diagnosis and less often symptomatic.
Perioperative Radiation and Imatinib Therapy
In the imatinib era, perioperative radiation was not used, but 24 patients (80%) received perioperative imatinib therapy, with 21 patients (70%) receiving neoadjuvant imatinib, 12 patients (40%) receiving adjuvant imatinib, and 9 patients (30%) receiving both (Table 2) . Neoadjuvant imatinib was administered for a median of 7.7 months (range 3-62 months), and the median size change was -28% (range -55 to ?18%; Fig. 1a ). This was equal to a partial Response Evaluation Criteria in Solid Tumors (RECISTs) rate of 42% and a stable disease rate of 58%. The median residual viable tumor (when quantified) was 20% (range 0-100%; Fig. 1b) . Only one patient demonstrated an appreciable increase in tumor size after neoadjuvant imatinib (?18%), but the tumor was less than 1% viable at pathologic analysis. Another tumor was 100% viable, yet had a stable size (-5%) and contained KIT exon 11 and 17 mutations.
The median mitotic rate for the resected specimens was 0, compared with 8 (range 0-50) for the 12 patients who had an available pretreatment mitotic rate (Fig. 1c) . Of 12 patients treated with adjuvant imatinib for a median of 2.8 years (range 0.1-6.5 years), 8 still were receiving therapy at the last follow-up visit.
Surgery
Only 3% of the patients underwent radical surgery with abdominoperineal resection or total pelvic exenteration in the imatinib era compared with 59% in the pre-imatinib era (p \ 0.0001; Table 2 ). Instead, patients more commonly underwent low anterior resection (37 vs. 12%) and local excision (60 vs. 29%). Despite less radical surgery, the R0 margin rate was similar ( Table 2) .
Given the trend toward more Miettinen high-risk patients in the pre-imatinib era (Table 1) , we also separately analyzed 34 high-risk patients, 13 of whom received neoadjuvant imatinib (patient characteristics presented in Table S1 ). Only four of the high-risk neoadjuvant imatinib patients (31%) had positive margins, compared with 15 (71%) of 21 patients who did not receive neoadjuvant imatinib (p = 0.03). Among the high-risk patients, low anterior resection and local excision were more common with neoadjuvant imatinib (12 of 13 patients, 92%) than without it (10 of 21 patients, 48%; p = 0.02). 
Outcome of Treatment
In the imatinib era, the 5-year OS, DSS, and RFS were significantly higher, at 91, 100, and 82% compared with 47, 61, and 44% ( Fig. 2a-c ). Recurrence developed in 15 patients at a median of 2.3 years (range 0.5-6.1 years) after the initial surgery, including 8 patients with isolated distant recurrences, 1 patient with isolated local recurrence, and 6 patients with both. No local recurrences have occurred in the imatinib era, whereas the pre-imatinib era saw five recurrences (excluding two R2 resections; 5-year local RFS of 100 vs. 63%; p = 0.002; Fig. 2d ). Likewise, distant RFS also was greater in the imatinib era (Fig. 2e) . Among the high-risk patients (Fig. 3) , we found that those who had received any perioperative imatinib therapy (n = 15) had a longer 5-year OS (91 vs. 47%; p = 0.049) than those who had not (n = 19), with a trend for a better 5-year DSS (100 vs. 65%; p = 0.051), 5-year local RFS (100 vs. 74%; p = 0.077), and 5-year distant RFS (71 vs. 41%; p = 0.051).
Three patients experienced distant recurrence in the imatinib era approximately 3 years after surgery ( Table S2) . One of these patients had not been treated with imatinib, and the other two patients had received respectively 1.2 and 1.4 years of perioperative imatinib. All three patients had undergone metastasectomy, with preoperatively initiated imatinib continued to last follow-up visit for two of the patients. At the last follow-up visit, all three were alive and disease free at respectively 5.3, 12.6, and 13.0 years.
In contrast, during the pre-imatinib era, five patients had isolated distant recurrences, one patient had isolated local recurrence, and six patients had both. Four patients eventually received imatinib once the drug became available. Only two patients underwent metastasectomy, and only one of them was alive without disease receiving imatinib at the last follow-up visit at 16.4 years. Altogether, 9 of 12 patients who experienced recurrence in the pre-imatinib era died of GIST, whereas no deaths due to GIST have occurred in the imatinib era.
We tested the association of survival with other surgical factors. The patients with positive margins exhibited no difference in OS, DSS, or distant RFS (not shown). Local recurrence was seen during the pre-imatinib era in both margin-positive and margin-negative patients, but not in the imatinib era, not even in margin-positive patients (Fig. S1 ). Multivariate analysis to assess the individual contribution of clinicopathologic risk factors, era, perioperative imatinib, and margins was not possible due to the small number of patients and events.
DISCUSSION
Our report is distinct from reports of other modern series. [13] [14] [15] [18] [19] [20] First, our data represent the largest singleinstitution experience, coming from a prospectively maintained database with mature follow-up evaluation, as opposed to multiple institutions in which treatment strategies and follow-up patterns vary. Our series spans the historical and imatinib eras, whereas some publications report only on the recent era. 14, 15, 18, 19 Some studies included patients who did not receive imatinib either due to lack of availability (pre-imatinib) or because it was not thought to be indicated clinically. Often, these patients were analyzed as one group or without clear designation. 13, 18, 20 Finally, we were able to classify the Miettinen risk groups for 96% of our patients, whereas in many other reports, the risk status often is unclear or there was no comparison group. Thus, we were able to compare the outcome for high-risk patients (76% of our cohort) by whether they received perioperative imatinib or not.
For primary GISTs, neoadjuvant imatinib can induce tumor shrinkage, although complete response is rare. 11, 18, 21 In six retrospective series comprising 83 patients who had rectal GIST treated with neoadjuvant imatinib, 60 patients (72.3%) had a partial response, 18 (21.7%) had stable disease, 3 had (4.8%) a complete response, and 1 (1.2%) had progressive disease according to RECIST. [13] [14] [15] [18] [19] [20] Our study adds another 21 patients treated with neoadjuvant imatinib. However, our partial response rate was lower, at 42%. Nevertheless, size decrease is not always a reliable indicator of response in GIST, with density on computed tomography often a better indicator. 22 Our patients had a median of only 20% residual viable tumor and a median mitotic index of 0 at surgery, consistent with robust treatment effects. Lack of treatment response should prompt tumor mutation analysis because one patient with 100% viable tumor at surgery had an imatinib-resistant secondary mutation.
The imatinib era was associated with more rectal and sphincter preservation. Although it has become clear that GIST does not require regional lymphadenectomy, 23 neoadjuvant imatinib contributed to smaller operations. Among 34 high-risk patients, 12 (92%) of 13 patients who received neoadjuvant imatinib underwent low anterior resection or local excision compared with only 10 (48%) of 21 patients who did not. This high rate of organ preservation was consistent with some, [13] [14] [15] 18 but not all, 19, 20 previous reports. Historically, radical surgery for rectal GIST was associated with less local recurrence. 24 Remarkably, in our series, although one third of the patients had positive margins in each era, no local recurrences were observed in the imatinib era. Similarly, among the high-risk patients, no local recurrences were experienced by patients who received perioperative imatinib compared with a local recurrence rate of 26% at 5 years for the patients who did not (Fig. 3c) . Although the rates of positive margins were similar globally by era, for the high-risk patients who received neoadjuvant imatinib, only 31% had positive margins compared with 71% of those who did not.
Taken together, the aforementioned data suggest that neoadjuvant imatinib is associated with more frequent complete resection and lack of local recurrence, although adjuvant imatinib likely also contributed to the latter. Five of six retrospective series had similar findings with regard to margins, with 46 (90%) of 51 patients who underwent neoadjuvant imatinib and surgery in those studies showing negative margins compared with 33 (52%) of 63 patient who did not. [13] [14] [15] 18, 19 Another study 20 showed no difference, although both groups had high rates of negative margins.
For patients undergoing local excision in the absence of perioperative imatinib treatment, high local recurrence rates have been reported compared with radical resection. 18, 24, 25 However, our data suggest that this does not hold true in the modern era. Because lymph node involvement is extremely rare, 23 lower rectal GISTs often can be removed by full-thickness local excision either transanally or transvaginally. 26, 27 In our experience, local excision also can be accomplished by a transabdominal approach, which is facilitated by the high-resolution optics of robotic surgery, allowing precise minimally invasive local excision that may include the prostatic capsule, vaginal wall, portions of the levator ani, or the muscular wall of the rectum. For a rectal GIST requiring transabdominal resection, we prefer the low anterior resection as opposed to local excision when a majority of the rectum circumference is compromised. However, a formal total mesenteric excision is not necessary. In our experience during the imatinib era, abdominoperineal resection with colostomy was necessary for only one patient (3%) due to direct involvement of the anal sphincters. In general, we consider that all distal rectal GISTs should be performed for local excision provided a negative margin can be obtained and the anal sphincter mechanism can be preserved. Based on our experience, we would accept a close or microscopically positive (R1) margin if the patient had been responsive to imatinib. However, if sacrifice of the sphincter is necessary for tumor removal, or if the patient is at high risk for fecal incontinence postoperatively (poor baseline sphincter function), we would consider abdominoperineal resection. Figure S2 shows a proposed algorithm for the surgical management of rectal GIST. Interpretation of oncologic outcome in previous studies is limited by the lack of clear risk stratification and appropriate comparison groups, and in some cases, unclear reasons for lack of imatinib treatment. Huynh et al. 13 saw longer disease-free survival (DFS) and local RFS with imatinib but no difference in OS for 16 patients who received perioperative imatinib compared with 29 patients who did not, yet detailed risk stratification was not reported by group. Jakob et al. 18 reported longer OS, DFS, and local RFS for 21 patients who received perioperative imatinib compared with 15 patients who did not, again without reporting the risk categories. Tielen et al. 20 showed longer DFS for 22 high-risk patients receiving perioperative imatinib compared with 10 undesignated patients, with no difference in OS. In this report, we show dramatically higher OS, DSS, and local and distant RFS in the imatinib era compared with the pre-imatinib era. Likewise, for highrisk patients alone (76% of our cohort), these findings remained consistent. We believe this represents the bestcontrolled evidence to date supporting the association of perioperative imatinib with reduced local and distant recurrence and improved DSS and OS.
Unlike local recurrences, distant recurrences were reduced but not prevented (Fig. 3c, d ). However, distant recurrences were found only after cessation of adjuvant imatinib. Based on prospective trials of adjuvant imatinib, 9, 28 it is our practice to prescribe at least 3 years of adjuvant imatinib after resection of high-risk rectal GIST. Although the Z9000/Z9001 studies showed no difference in recurrence, with positive margins regardless of imatinib treatment, 29 we did not see any local recurrences during the imatinib era even with positive margins, whereas local recurrences were seen with positive margins during the pre-imatinib era (Fig. S1 ). This suggests that adjuvant imatinib may contribute to suppression of local recurrence after positive margins. Thus, in the face of positive microscopic margins, we generally prescribe adjuvant imatinib instead of more extensive re-resection (Table S3) .
Tyrosine kinase inhibitors have changed the natural history of GIST 4 and of many other solid tumors. guiding principle has been matching of genomic analysis to treatment. In GIST, KIT exon 11 deletions may benefit most from imatinib. 31 Other mutations, such as KIT exon 9, may require a higher dose, whereas a common subset of PDGFRa mutations (D842V) does not respond to imatinib. 4 We did not detect any PDGFRa mutations in 31 tumors. Among 66 tumors tested in the six retrospective series, only 1 PDGFRa mutation (1.5%) was found, although the rate is 10% in the overall GIST population. 4 The 30-day complication rate was available from our prospectively maintained record for the imatinib era. Grade 1 complications occurred for 5 (17%) of 30 patients ( Table 2 ), all of which were managed with bedside and/or oral medical therapy. Grade 3 complications related to the rectal repair developed for 3 (17%) of 18 patients in the local excision group, none of whom had undergone neoadjuvant or adjuvant imatinib. Two of these patients experienced dehiscence of the repair after transanal excision. Both were treated successfully by diverting stomas that were later reversed. For another patient, suture line bleeding developed after a transanal excision, which required control in the operating room. Among the patients who received any perioperative imaitinib (n = 24), the only complications were grade 1 (n = 4, 17%). Overall, we believe this is a low and acceptable complication rate for perioperative imatinib. We recommend that clinicians clearly discuss with patients the risk of complications related to transanal local excision in the context of the organ preservation achieved.
Although this study represents the largest single-institution experience of rectal GIST, it had several limitations. Although this is the largest series, the numbers still were small and collected over a longer period (34 years) than in the other series. The data were quite complete overall, but complication data were not available for the pre-imatinib era. Finally, these data were retrospective in nature, and as a result may have been subject to undetected bias.
In conclusion, for high-risk rectal GIST, neoadjuvant imatinib treatment was associated with higher rates of organ and sphincter preservation and lower rates of positive margins. Despite positive margins in up to one third of the patients, no local recurrences were experienced by those who received perioperative imatinib. Imatinib treatment was associated with reduced distant recurrence, and for those who did experience distant recurrence, salvage was possible with further imatinib treatment and surgery, resulting in no disease-related deaths during the imatinib era to date. Overall, we believe this approach yields better organ preservation without compromising (and possibly improving) oncologic outcome. For this rare subset of an uncommon disease for which prospective study is difficult, we believe our data support perioperative imatinib and organ preservation as the preferred approach for most rectal GISTs.
